The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 27, 2018

Filed:

Dec. 01, 2014
Applicant:

Welt Bio-molecular Pharmaceutlical, Llc, Armonk, NY (US);

Inventors:

Sydney Welt, Armonk, NY (US);

David Kostyal, Akron, OH (US);

Rachel S Welt, Armonk, NY (US);

Virginia Raymond, Armonk, NY (US);

Jonathan A Welt, Armonk, NY (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C12N 5/20 (2006.01); C12N 15/13 (2006.01); C07K 16/42 (2006.01); C12N 5/16 (2006.01);
U.S. Cl.
CPC ...
C07K 16/4283 (2013.01); C12N 5/163 (2013.01); C07K 16/2803 (2013.01); C07K 2317/14 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01);
Abstract

The present invention relates to monoclonal antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias. Monoclonal antibodies designated mAb4-2b, mAb1-1, mAb2-2b and mAb3-2b were produced by hybridoma cell lines (ATCC deposit no. PTA-121716), (ATCC deposit no. PTA-121719), (ATCC deposit no. PTA-121717), and (ATCC deposit no. PTA-121718), respectively. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of B-cell malignancies, including B-cell lymphomas and leukemias.


Find Patent Forward Citations

Loading…